Compares a copy of semaglutide with Wegovy in adults with obesity
Tests a semaglutide injection against Wegovy in adults with obesity over 48 weeks.
Plain-language title generated from the registry record
Registry title: Efficacy and Safety of Semaglutide Injection Vs WEGOVY® in Chinese Obese Patients
Key facts
- Where
- Beijing, ChinaSee the site
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07036172, who can take part
Where in China
- Peking University People's HospitalBeijing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
- Trial code
- NCT07036172
- Record updated
- 25 June 2025
- Original description
This is a 48-week randomized, open-label, parallel-controlled biosimilar comparison study comparing the efficacy, safety and immunogenicity of the investigational drug and WEGOVY® in patients with obesity. Eligible participants will be screened and randomized to the experimental group and the active comparator group at a ratio of 1:1 , semaglutide injection or WEGOVY® injection will be given once weekly for 44 weeks, following by a safety follow up of 4 weeks. All participants received a lifestyle intervention that involved counselling on diet and physical activity.Read full original descriptionShow less
A Multicenter, Randomized, Open-label, Parallel-controlled Phase III Clinical Study Comparing the Efficacy and Safety of Semaglutide Injection and WEGOVY® in Chinese Obese Patients
This is a 48-week randomized, open-label, parallel-controlled biosimilar comparison study comparing the efficacy, safety and immunogenicity of the investigational drug and WEGOVY® in patients with obesity. Eligible participants will be screened and randomized to the experimental group and the active comparator group at a ratio of 1:1 , semaglutide injection or WEGOVY® injection will be given once weekly for 44 weeks, following by a safety follow up of 4 weeks. All participants received a lifestyle intervention that involved counselling on diet and physical activity.
Inclusion: Male or female, aged ≥18 years and ≤75 years at the time of signing informed consent；; BMI ≥28 kg/m2；; A self-reported change in body weight no more than 5% within 90 days before screening.
Exclusion: Previous or planned (during the trial period) obesity treatment with surgery or a weight-loss device; Uncontrolled hypertension, any of the following: myocardial infarction, stroke, hospitalisation for unstable angina, or transient ischaemic attack within the past 6 months prior to screening; History of type 1 and type 2 diabetes; Personal or first-degree relative(s) history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma; A history or presence of suspected depression or other mental disorders; History of malignant neoplasms within the past 5 years prior to screening; History or presence of chronic or acute pancreatitis; Patient Health Questionnaire-9 score of ≥15 at screening.